Marcaine
Uterine Corpus Leiomyoma
University of California, IrvineSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Uterine Corpus Leiomyoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rocuronium Ion Stony Brook University | Phase 4 | BB |
Cyclobenzaprine Christiana Care Health Services | Phase 4 | B |
Human Chorionic Gonadotropin Lebanese University | Phase 1/2 | CCC |
Indocyanine Green Chen Chunlin | Early Phase 1 | CC |
Desflurane Chosun University Hospital | N/A | D |
Ramifentanyl Chosun University Hospital | N/A | D |
lfa102 Novartis Pharmaceuticals | Phase 1 | NR |
Same molecule, other indications
Marcaine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →